ROCKVILLE, Md., April 16, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX ), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that pre-clinical data from programs based on its Dual-Affinity Re-Targeting (DART®) bi-specific technology will be presented at the 2015 American Association for Cancer Research (AACR) Annual Meeting in Philadelphia, PA by the Company and Pfizer, Inc., one of MacroGenics' collaboration partners. These posters include:
Title: DART® molecules with enhanced DR5 agonistic activity for improved cancer cell cytotoxicity
Time: Monday, April 20, 2015, from 1:00 - 5:00pm ET
Location: Poster section 25
Poster Board Number: 6
Abstract Number: 2464
Presented by: MacroGenics, Inc.
Title: Bispecific redirected T-cell immunotherapy targeting P-cadherin expressing tumors
Time: Monday, April 20, 2015, from 1:00 - 5:00pm ET
Location: Poster section 25
Poster Board Number: 18
Abstract Number: 2476
Presented by: Pfizer, Inc.
Title: Bio-distribution and tumor targeting of a P-cadherin x CD3 bi-specific redirected T-cell molecule using fluorescence molecular tomography imaging
Time: Wednesday, April 22, 2015, 8:00 am - 12:00pm ET
Location: Poster section 16
Poster Board Number: 2
Abstract Number: 5111
Presented by: Pfizer, Inc.
About the DART Platform
MacroGenics' Dual-Affinity Re-Targeting (DART) platform enables the targeting of multiple antigens or cells by using a single molecule with an antibody-like structure. The Company has created over 100 DART molecules which have been configured for the potential treatment of cancer, autoimmune disorders and infectious disease. These DART molecules can be tailored for either short or prolonged pharmacokinetics and have demonstrated good stability and attractive manufacturability.
About MacroGenics, Inc.
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. The company generates its pipeline of product candidates from its proprietary suite of next-generation antibody-based technology platforms. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com . MacroGenics is a registered trademark of MacroGenics, Inc.
Cautionary Note on Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company's strategy, future operations, clinical development of the Company's therapeutic candidates, milestone or opt-in payments from the Company's collaborators, the Company's anticipated milestones and future expectations and plans and prospects for the Company and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and enrollment of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, expectations for regulatory approvals, other matters that could affect the availability or commercial potential of the Company's product candidates and other risk factors described in the Company's filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.
Jim Karrels, Senior Vice President, CFO MacroGenics, Inc. 1-301-251-5172, Karen Sharma, Vice President MacDougall Biomedical Communications 1-781-235-3060,
